CANCAP02: A study into the pharmacodynamic biomarker effects of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (RP).

被引：0
|
作者：
Pacey, Simon
Corbacho, Javier Garcia
Shah, Nimish
Brat, Ola
Warren, Anne
Baird, Richard D.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.97
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
97
引用
收藏
页数：2
相关论文
共 31 条
  • [31] Phase I study of orally administered 14Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism, excretion, and pharmacokinetics in patients with advanced solid malignancies
    Alexander MacDonald
    Graeme Scarfe
    Dominic Magirr
    Tinnu Sarvotham
    Julie Charlton
    Wolfram Brugger
    Emma Dean
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 787 - 795
1234